On June 26, Akeso fell 3.16% in regular trading, trading at HK$82.75/share with turnover of HK$382 million, as the stock approached its 52-week low of HK$80.20.

The decline reflects continued selling pressure following the company's ASCO presentation of positive overall survival data from the HARMONi-6 trial for ivonescimab. Despite the landmark clinical results demonstrating a 34% reduction in death risk for squamous NSCLC patients, the stock has fallen over 30% from its post-data high as investors locked in gains. The board's approved HK$200 million share repurchase plan and management's planned purchase of up to HK$50 million in shares have yet to stem the selling.

The broader biotech sector remained weak, with Innovent Biologics down 1.58%, Remegen down 1.28%, and BeiGene down 0.42%, reflecting persistent sector-wide headwinds that compounded stock-specific profit-taking pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)